Option chain shows key data for Next Technology Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Next Technology Holding.

Next Technology Holding (NASDAQ:NXTT) Stock, Option Chain

Next Technology Holding

WeTrade Group

Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CYCC

DAVE

EFSH

GRPN

HNRG

IAUX

KAPA

MAPS

MULN

MVST

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

RKLB

SAVE

SIDU

SYRS

Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

xr:d:DAFqNaIkdw0:2,j:153520640059868796,t:23073113

Intraday Update

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

xr:d:DAFhS-kD63I:2,j:45998648077,t:23042711

ALGM

ALKS

ALLR

ATCH

ATPC

AZTR

BBLG

BLCO

CJET

CONN

DRMA

ENPH

FLEX

GERN

GOOGL

KORE

LITM

MANH

NAAS

NIVF

NUWE

NUZE

PIRS

ROKU

SAGE

SOAR

SYNX

TKNO

TSLA

ULTA

VSTM

Vintage Wine Estates, Inc. - Common Stock

WFRD

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Next Technology Holding Inc

Lifeist Wellness Inc

Offerings

GIFT

Giftify Announced It Has Canceled Registered Direct Offering Due To Market Condition

Loop Capital analyst Eric Beder maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $500 to $550.

Price Target

Analyst Ratings

MSFT

Loop Capital Maintains Buy on Microsoft, Raises Price Target to $550

Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025
TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA
Fibromyalgia affects more than 10 million adults in the U.S., who are mostly women
TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and first new drug for its treatment in more than 15 years
NDA based on two statistically significant Phase 3 studies of TNX-102 SL for the management of fibromyalgia, in which TNX-102 SL was generally well tolerated
CHATHAM, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) today announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing approval for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia. TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.

Biotech

General

TNXP

Tonix Pharmaceuticals Announces PDUFA Goal Date Of August 15, 2025, For FDA Decision On U.S. Marketing Approval For TNX-102 SL For Fibromyalgia; NDA Based On Two Statistically Significant Phase 3 Studies Of TNX-102 SL For The Management Of Fibromyalgia, In Which TNX-102 SL Was Generally Well Tolerated

WIIM

IIPR

Innovative Industrial Properties shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>), a leading technology provider of enterprise and government mobility solutions, is collaborating with Saudi Awwal Bank (SAB Bank) to launch its last-mile shuttle operations in Riyadh, Saudi Arabia. This initiative builds on the successful launch of the Riyadh Metro and aims to bridge first- and last-mile connectivity gaps, ensuring seamless access for SAB employees to the city's new metro system.
SAB Bank, one of Saudi Arabia's leading financial institutions, is leveraging Swvl's first- and last-mile shuttle services to streamline employee commutes. Swvl provides shuttle buses that connect SAB employees to and from the nearest metro stations, ensuring a smooth and enhanced transportation experience.
Powered by Swvl's proprietary technology, the first- and last-mile shuttle services are designed to address critical connectivity gaps between business hubs and metro stations. By integrating virtual stops, Swvl brings commuters closer to Riyadh Metro stations, eliminating the inconvenience of long walks and ensuring a smooth transition to and from the metro. This service plays a crucial role following the metro launch, as it enhances accessibility, encourages public transport adoption, and provides a reliable, convenient alternative to private vehicles.
The Riyadh Metro has officially commenced operations, marking a significant milestone in the city's urban mobility transformation. The phased launch began on December 1, 2024. This comprehensive network encompasses six lines, covering a total of 176 kilometers and featuring 85 stations, including four main stations. The Riyadh Metro is designed to provide a sustainable, reliable, and efficient alternative to private vehicles, aiming to reduce traffic congestion and enhance connectivity across the capital.

Global

SWVL

Swvl Is Collaborating With Saudi Awwal Bank To Provide Last-Mile Shuttle Services For SAB Bank Following Riyadh Metro Launch

Guidance

CRNC

Cerence AI Reaffirms Q1 And FY 2025 Guidance Previously Disclosed With FY 2024 Results On November 21, 2024

Giftify, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFT#NASDAQ">GIFT</a>) (the "Company"), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining &amp; entertainment experiences, today announced that its previously announced registered direct offering with Craft Capital Management, LLC has been cancelled.
Giftify management decided to cancel the offering due to market conditions.

Giftify Cancels Registered Direct Offering Due To Market Conditions

&nbsp;Confirmed By Nasdaq Moot Letter; Further Hearing No Longer Required

MDAI

Spectral AI Regains Compliance With Nasdaq Listing Standards

Dividends

CION

Cion Investment Corporation Announced A Special Distribution of $0.05 per Share, Payable On January 27, 2025 To Shareholders Of Record On December 30, 2024

New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free survival in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)
If approved, taletrectinib represents a potential best-in-class treatment option for patients with advanced ROS1+ NSCLC
U.S. Food and Drug Administration (FDA) has assigned a target action date of June 23, 2025
Nuvation Bio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company's NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025. Priority Review designation underscores the significant advancement taletrectinib may offer patients with ROS1+ NSCLC, for which there remains a high unmet need for new treatment options. Taletrectinib previously received Orphan Drug Designation and is the only ROS1 TKI currently in development that has received Breakthrough Therapy Designation from the U.S. FDA for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs.

NUVB

Nuvation Bio Announces The U.S. FDA Accepts For Priority Review Nuvation Bio's New Drug Application For Taletrectinib For The Treatment Of Advanced ROS1-Positive Non-Small Cell Lung Cancer

Additional $3.4M Possible From Warrant Exercises

VVOS

Vivos Therapeutics Announces $3.5M Registered Direct Offering Of 709,220 Shares Of Common Stock At $4.935

After a review of relevant portions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), as well as a review of various non-authoritative interpretations and guidance authored by certain major U.S. accounting firms regarding the FASB ASC, on December 20, 2024, the Company's management has concluded that U.S. Generally Accepted Accounting Principles ("GAAP") requires that a borrower's balance outstanding on a revolving line of credit be reflected as a current liability when the loan agreement includes provisions for both (i) a required lock box arrangement with a lender in which the borrower does not have the ability to avoid using working capital to repay the amounts outstanding, whether or not the borrower has the ability to re-borrow funds based on its regular borrowing base calculation in the ordinary course of business, and (ii) a "subjective acceleration clause" which is defined in accordance with GAAP to include loan provisions that permit the lender to accelerate the loan upon the occurrence of a "material adverse change".&nbsp;
The Company's management has further concluded that the classification as a current liability is required in accordance with GAAP even if (i) it is deemed that the "subjective acceleration clause" is not probable to be utilized by the lender within twelve months from the date of the balance sheet and (ii) the maturity date of the loan extends more than twelve months from the date of the balance sheet.

Optical Cable Corp Revises Loan Reporting to Align with Updated GAAP Guidelines

FibroBiologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN LTD. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of $5 million was funded upon entry into the SEPA. Subject to the satisfaction of certain conditions, the second tranche of $5 million will fund after the filing of a registration statement covering the resale of the shares issuable to Yorkville under the promissory notes, and the third tranche of $5 million will fund following the effectiveness of the registration statement and receipt of shareholder approval in satisfaction of Nasdaq rules. FibroBiologics can sell an additional $10 million of its common stock to Yorkville, subject to Yorkville's consent and other conditions, while the convertible promissory notes remain outstanding.

Financing

FBLG

FibroBiologics Has Entered Into A Standby Equity Purchase Agreement With YA II PN LTD. To Sell Up To $25M In The Aggregate Of Its Common Stock To Yorkville Over The Course Of 2-Years

Contracts

NVEE

NV5 Awarded $5M 5-Year Contract By The Georgia Department Of Transportation

Analysts' ratings for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00, and a low estimate of $105.00. A 8.65% drop is evident in the current average compared to the previous average price target of $159.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958894_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Novo Nordisk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$156.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Novo Nordisk. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Novo Nordisk compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Novo Nordisk's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Novo Nordisk analyst ratings.</a>
<h2>Get to Know Novo Nordisk Better</h2>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Novo Nordisk displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 21.42%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Novo Nordisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Novo Nordisk's ROE excels beyond industry benchmarks, reaching 23.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Novo Nordisk's ROA stands out, surpassing industry averages. With an impressive ROA of 7.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Novo Nordisk Stock

INVZ

Innoviz Secures $80M Multi-Year NRE Payment Plan With Key Customers; Expects $40M In 2025 And Additional Revenue From Ongoing LiDAR Sales And New Programs

In the latest quarter, 4 analysts provided ratings for Encore Capital Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECPG#NASDAQ">ECPG</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Encore Capital Gr, presenting an average target of $62.25, a high estimate of $66.00, and a low estimate of $58.00. This current average has increased by 6.87% from the previous average price target of $58.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958871_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Encore Capital Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Encore Capital Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Encore Capital Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Encore Capital Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Encore Capital Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ECPG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Encore Capital Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Encore Capital Gr: A Closer Look</h2>
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchase portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumer repay their obligations and work toward financial recovery. Encore has only a reportable segment being portfolio purchasing and recovery.
<h3>Financial Milestones: Encore Capital Gr's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Encore Capital Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.56% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Encore Capital Gr's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 8.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Encore Capital Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.01%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Encore Capital Gr's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.62%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 3.39, Encore Capital Gr faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ECPG

Analyst Expectations For Encore Capital Gr's Future

In the last three months, 4 analysts have published ratings on PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PotlatchDeltic, presenting an average target of $47.75, a high estimate of $51.00, and a low estimate of $45.00. This current average has increased by 0.17% from the previous average price target of $47.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1734958857_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of PotlatchDeltic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Matthew McKellar</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PotlatchDeltic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of PotlatchDeltic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PotlatchDeltic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of PotlatchDeltic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PotlatchDeltic analyst ratings.</a>
<h2>All You Need to Know About PotlatchDeltic</h2>
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
<h3>Unraveling the Financial Story of PotlatchDeltic</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining PotlatchDeltic's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -3.91% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: PotlatchDeltic's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PotlatchDeltic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.16%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): PotlatchDeltic's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: PotlatchDeltic's debt-to-equity ratio is below the industry average. With a ratio of 0.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For PotlatchDeltic's Future

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CEVA, revealing an average target of $34.5, a high estimate of $40.00, and a low estimate of $28.00. Witnessing a positive shift, the current average has risen by 23.21% from the previous average price target of $28.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734958831_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive CEVA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Suji Desilva</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CEVA. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CEVA compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CEVA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CEVA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CEVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CEVA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind CEVA</h2>
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
<h3>CEVA: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: CEVA displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 13.02%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: CEVA's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.82%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CEVA's ROE excels beyond industry benchmarks, reaching -0.5%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CEVA's ROA excels beyond industry benchmarks, reaching -0.43%. This signifies efficient management of assets and strong financial health.
Debt Management: CEVA's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CEVA

Deep Dive Into CEVA Stock: Analyst Perspectives (4 Ratings)

Cigna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has fallen 10.85% since its last report. The company recently reported that it has 3.19 million shares sold short, which is 1.15% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734958826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cigna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna's peer group average for short interest as a percentage of float is 8.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Cigna's Recent Short Interest

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Next Technology Holding (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) just reported results for the second quarter of 2024.<ul><li>Next Technology Holding reported earnings per share of -$1.92.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/nxtt-stock-earnings-next-technology-holding-for-q2-of-2024/">NXTT Stock Earnings: Next Technology Holding Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NXTT Stock Earnings: Next Technology Holding Reported Results for Q2 2024

Next Technology Holding ( ($NXTT) ) just unveiled an update. Next Technology Holding Inc. revamped its bitcoin acquisition strategy by amending its...

Next Technology Holding Enhances Bitcoin Strategy and Operations

The latest announcement is out from Next Technology Holding ( ($NXTT) ). Next Technology Holding Inc. has appointed Ms. Eve Chan as the new Chief F...

Next Technology Holding Appoints New CFO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Next Technology Holding (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) just reported results for the second quarter of 2024.<ul><li>Next Technology Holding reported earnings per share of -$1.92.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/nxtt-stock-earnings-next-technology-holding-for-q2-of-2024/">NXTT Stock Earnings: Next Technology Holding Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Press Releases

Next Technology Holding Inc. Announces Receipt of Staff Determination Letters from Nasdaq.

Comments

Next Technology Holding

Next Technology Holding (NXTT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga